UCB Japan to License H2-Receptor Antagonist STOGAR Tab.

UCB Japan announced on June 7 that it has signed an agreement with Korean company Boryung Pharmaceutical, whereby Boryung will exclusively license to sell in Korea STOGAR tab. 5 and STOGAR tab. 10, H2 receptor antagonists UCB Japan manufactures and sells in Japan. Launched in April 2000, H2 receptor antagonist STOGAR tab. has been used in the treatment of gastritis and peptic ulcer. Boryung Pharmaceutical will start clinical development with the aim of launching STOGAR tab. in 2006.

()a href="http://www.japancorp.net/Article.Asp?Art_ID=10270" target="_blank">Japan Corporate News Network